Why Century Therapeutics, Inc.’s (IPSC) Stock Is Down 5.83%
As of Friday, August 28, Century Therapeutics, Inc.’s IPSC share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Commentary & Analysis
Why Century Therapeutics, Inc.’s (IPSC) Stock Is Up 5.61%
As of Wednesday, August 19, Century Therapeutics, Inc.’s IPSC share price has surged by 5.61%, which has investors questioning if this is right time to sell.Michael Rose
Why Century Therapeutics, Inc.’s (IPSC) Stock Is Down 5.71%
As of Friday, July 31, Century Therapeutics, Inc.’s IPSC share price has dipped by 5.71%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Century Therapeutics, Inc.’s (IPSC) Stock Is Up 5.69%
As of Thursday, July 30, Century Therapeutics, Inc.’s IPSC share price has surged by 5.69%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Century Therapeutics, Inc.’s (IPSC) Stock Is Down 6.67%
As of Monday, July 13, Century Therapeutics, Inc.’s IPSC share price has dipped by 6.67%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | IPSC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $378.4 | $289.2 | 33% |
|
| Shares Out (Mil) | 205.8 | 54.1 | 77% |
|
| Institutional Ownership | 97.2% | 93.1% | 73% |
|
| Float (Mil) | 101.4 | 42.2 | 61% |
|
| Beta | 1.60 | 0.94 | 85% |
|
| Avg Daily Volume (000s) | 421 | 451 | 57% |
|
| Price Change (52-week) |
346.4% | 59.8% | 99% |
|
| Growth | IPSC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 29.1% | (10.1%) | 84% |
|
| EPS (5yr) | 56.5% | 15.9% | 95 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.1% | (15.6%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 3 | 4 | |
| Current EPS | ($0.110) | ($0.450) | ($0.453) | |
| Month Ago EPS | ($0.123) | ($0.460) | ($0.458) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.123) | ($0.460) | ($0.458) | |
| Year/Year Chg | (35.3%) | 305.4% | 206.3% | |
| Financials | IPSC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($110) | ($43) | 10% |
|
| EPS (TTM) | ($0.766) | ($1.500) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($87) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $35 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $268 | $190 | 28% |
|
| Valuation | IPSC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.62 | 2.84 | 42% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IPSC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (38.4%) | (47.8%) | 14% |
|
| ROE | (49.7%) | (55.0%) | 15% |
|
| Liabilities to Assets | 19.0% | 29.7% | 12% |
|
| F-Score | 1 | 3 | 1% |
|
Century Therapeutics, Inc. did not pass any screens on 9/3/2026.
